Racivir

Racivir is an oral, once-daily cytidine nucleoside analog that we are developing as an HIV therapy for use in combination with other approved HIV drugs. We have completed a Phase 2 clinical trial, Study 201, to assess the safety, tolerability and antiviral effect of a 600 mg dose of Racivir head-to-head against lamivudine in HIV-infected, treatment-experienced patients with the M184V mutation who have been on lamivudine therapy. The goal of this study was to evaluate the benefit of Racivir in patients carrying the M184V mutation by replacing lamivudine with Racivir in existing therapies. (www.pharmasset.com)

Racivir Demonstrates Good Safety and Efficacy in Patients with NRTI-resistant HIV
4/03/07

Dosage Form/Administration

Racivir comes in tablet form and is taken by mouth once a day. It has not yet been determined whether racivir should be taken with or without food. Racivir is taken in combination with approved antiretroviral medications.

Contraindications

Individuals should tell a doctor about any medical problems before taking this medicine.

Possible Side Effects

Along with its desired effects, racivir may cause some unwanted effects. Although not all of these effects are known, headache and fatigue have been reported.

Drug and Food Interactions

A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

Manufacturer Information

Racivir
Pharmasset, Inc.
US Research Operations
1860 Montreal Road
Tucker, GA 30084
(678) 395-0035

HIV and AIDS: Top News Articles   HIV and AIDS: FDA-approved Treatments  HIV and AIDS: Experimental Treatments HIV and AIDS: Library of CME Programs